Dolutegravir Sodium - ≥99% , Human immunodeficiency virus type 1 integrase inhibitor, CAS No.1051375-19-9, Human immunodeficiency virus type 1 integrase inhibitor
Dolutegravir Sodium - ≥99% , Human immunodeficiency virus type 1 integrase inhibitor, CAS No.1051375-19-9, Human immunodeficiency virus type 1 integrase inhibitor
≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
🌡
Storage & shipping
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
📋
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
📚
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Descripción general
Integrase inhibitors are a new class of antiretroviral drugs blocking the action of HIV integrase, which catalyses several key steps in the life cycle of the virus and is essential for insertion of the viral genome into the host cell DNA. GSK1349572 is a next-generation HIV integrase (IN) inhibitor.
In vitro: GSK1349572 is a two-metal-binding HIV integrase strand transfer inhibitor whose mechanism of action was established through resistance passage experiments, integrase enzyme assays, mechanistic cellular assays and activity against viral strains resistant to other classes of anti-HIV agents. In a variety of cellular antiviral assays, GSK1349572 inhibited HIV replication with subnanomolar or low-nanomolar potency and with a selectivity index of 9,400. The protein-adjusted half-maximal effective concentration extrapolated to 100% human serum was 38 nM .
In vivo: No animial in vivo data are available for GSK1349572 so far.
Clinical trial: GSK1349572 was effective when given once daily without a pharmacokinetic booster and was well tolerated at all assessed doses. These findings support the assessment of once daily 50 mg GSK1349572 in phase 3 trials.
Specifications
Sinónimos
DOLUTEGRAVIR SODIUM SALT [MI] | Dolutegravir (sodium) | DOLUTEGRAVIR SODIUM COMPONENT OF TRIUMEQ | Dolutegravir sodium salt | Dolutegravir sodium [USAN] | DOLUTEGRAVIR SODIUM COMPONENT OF JULUCA | TIVICAY PD | Tivicay (TN) | HY-13238A | SODIUM (4R, 12AS)-9
Especificaciones y pureza
≥99%
Mecanismos bioquímicos y fisiológicos
Dolutegravir Sodium is an HIV-1 integrase inhibitor with an IC 50 of 2.7nM. No effect on total viral DNA synthesis in infected cells but blocks the integration of viral DNA into host DNA.
Condiciones de almacenamiento de almacenamiento
Store at -20°C
Enviado en
Ice chest + Ice pads
Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.
Tipo de acción
INHIBITOR
Mecanismo de acción
Human immunodeficiency virus type 1 integrase inhibitor
This compound belongs to the class of organic compounds known as pyridinecarboxylic acids and derivatives. These are compounds containing a pyridine ring bearing a carboxylic acid group or a derivative thereof.
External Descriptors
organic sodium salt
1. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck C, Subramanian S, Bolton E, Greiner R, and Wishart DS. ClassyFire: Automated Chemical Classification With A Comprehensive, Computable Taxonomy. Journal of Cheminformatics, 2016, 8:61.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
F2523368